Pharma Journalist -

M2GEN, a leading oncology-focused data and informatics company, announced a significant new five-year agreement with Merck, known as MSD outside the United States and Canada. Under the…
Read More...

Merck known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a New Drug Application…
Read More...

AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in…
Read More...

Moderna Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the first participants have been dosed in the Phase 2/3 study, called the…
Read More...

WuXi Biologics announced that it has entered into an equity agreement with Pfizer China to acquire its state-of-the-art biologics manufacturing facilities as well as its labor force in…
Read More...

Nurix Therapeutics, Inc. a biopharmaceutical company developing targeted protein modulation drugs,  announced that it is part of a collaboration sponsored by Alex’s Lemonade Stand…
Read More...

Ampio Pharmaceuticals a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, recently revealed preliminary positive…
Read More...

Takeda Pharmaceutical Company Limited announced a mutual agreement with IDT Biologika GmbH, a contract development and manufacturing organization, to utilize capacity at IDT previously…
Read More...

Gilead Sciences, Inc. and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement to co-develop and co-commercialize…
Read More...

Novartis announced new data that reinforce the transformational benefit of Zolgensma (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA). The…
Read More...